Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALGS NASDAQ:BTMD NASDAQ:ELDN NASDAQ:MDWD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALGSAligos Therapeutics$8.00+7.2%$7.64$3.76▼$46.80$45.61M2.7781,329 shs28,705 shsBTMDbiote$4.13+6.2%$4.02$3.04▼$7.25$212.82M1.2190,758 shs179,850 shsELDNEledon Pharmaceuticals$3.25-3.8%$3.16$2.38▼$5.54$202.40M-0.15708,054 shs1.28 million shsMDWDMediWound$18.37-0.9%$20.22$14.14▼$22.50$200.27M0.2158,694 shs253,213 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALGSAligos Therapeutics+7.24%-8.68%+0.63%+72.60%-34.02%BTMDbiote+6.17%-5.49%-1.90%+22.19%-42.16%ELDNEledon Pharmaceuticals-3.85%+0.62%+8.15%+13.24%+17.75%MDWDMediWound-0.86%-7.83%-5.65%+3.26%+5.09%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALGSAligos Therapeutics4.2748 of 5 stars3.54.00.04.83.01.70.0BTMDbiote2.9873 of 5 stars3.53.00.00.00.63.31.3ELDNEledon Pharmaceuticals1.6916 of 5 stars3.52.00.00.01.11.70.0MDWDMediWound2.2198 of 5 stars3.52.00.00.02.60.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALGSAligos Therapeutics 3.00Buy$70.00775.00% UpsideBTMDbiote 3.00Buy$8.0093.70% UpsideELDNEledon Pharmaceuticals 3.00Buy$10.00207.69% UpsideMDWDMediWound 3.00Buy$32.2575.56% UpsideCurrent Analyst Ratings BreakdownLatest ALGS, ELDN, MDWD, and BTMD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/25/2025ELDNEledon PharmaceuticalsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$12.006/18/2025ELDNEledon PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy$9.006/2/2025MDWDMediWoundOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$34.005/22/2025MDWDMediWoundHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$25.00 ➝ $31.00(Data available from 8/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALGSAligos Therapeutics$3.94M12.41N/AN/A($7.50) per share-1.07BTMDbiote$199.38M1.13$0.81 per share5.08($2.78) per share-1.49ELDNEledon PharmaceuticalsN/AN/AN/AN/A$1.98 per shareN/AMDWDMediWound$19.21M10.33N/AN/A$2.89 per share6.36Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALGSAligos Therapeutics-$131.21M-$17.51N/AN/AN/A-1,628.75%14.67%7.19%8/6/2025 (Estimated)BTMDbiote$3.16M$0.616.777.65N/A10.93%-19.44%20.12%8/6/2025 (Estimated)ELDNEledon Pharmaceuticals-$36.18M-$2.10N/AN/AN/AN/A-79.54%-41.62%8/18/2025 (Estimated)MDWDMediWound-$30.22M-$2.09N/AN/AN/A-110.45%-74.12%-30.92%8/13/2025 (Estimated)Latest ALGS, ELDN, MDWD, and BTMD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/18/2025Q2 2025ELDNEledon Pharmaceuticals-$0.23N/AN/AN/AN/AN/A8/13/2025Q2 2025MDWDMediWound-$0.55N/AN/AN/A$5.68 millionN/A8/6/2025Q2 2025ALGSAligos Therapeutics-$2.35N/AN/AN/A$0.43 millionN/A8/6/2025Q2 2025BTMDbiote$0.06N/AN/AN/A$49.52 millionN/A5/21/2025Q1 2025MDWDMediWound-$0.65-$0.07+$0.58-$0.07$5.20 million$3.96 million5/14/2025Q1 2025ELDNEledon Pharmaceuticals-$0.28-$0.08+$0.20-$0.08N/AN/A5/7/2025Q1 2025BTMDbiote$0.06$0.08+$0.02$0.37$47.25 million$48.99 million5/6/2025Q1 2025ALGSAligos Therapeutics-$2.80-$2.11+$0.69-$2.11$0.33 million$0.31 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALGSAligos TherapeuticsN/AN/AN/AN/AN/ABTMDbioteN/AN/AN/AN/AN/AELDNEledon PharmaceuticalsN/AN/AN/AN/AN/AMDWDMediWoundN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALGSAligos TherapeuticsN/A7.567.56BTMDbioteN/A1.421.14ELDNEledon PharmaceuticalsN/A13.9013.91MDWDMediWoundN/A2.151.99Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALGSAligos Therapeutics60.43%BTMDbiote21.68%ELDNEledon Pharmaceuticals56.77%MDWDMediWound46.83%Insider OwnershipCompanyInsider OwnershipALGSAligos Therapeutics4.80%BTMDbiote24.00%ELDNEledon Pharmaceuticals12.30%MDWDMediWound9.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALGSAligos Therapeutics906.11 million5.82 millionNo DataBTMDbiote19454.71 million41.58 millionNot OptionableELDNEledon Pharmaceuticals1059.88 million52.52 millionOptionableMDWDMediWound8010.81 million9.81 millionOptionableALGS, ELDN, MDWD, and BTMD HeadlinesRecent News About These CompaniesMediWound Ltd. to Announce Second Quarter 2025 Financial Results and Host Conference Call on August 14August 4 at 7:53 AM | quiverquant.comQMediWound to Report Second Quarter 2025 Financial ResultsAugust 4 at 7:30 AM | globenewswire.comHead to Head Analysis: MediWound (NASDAQ:MDWD) versus Vaxart (NASDAQ:VXRT)August 4 at 3:35 AM | americanbankingnews.comHere's What Could Help MediWound (MDWD) Maintain Its Recent Price StrengthJuly 24, 2025 | msn.comSargent Investment Group LLC Sells 52,500 Shares of MediWound Ltd. (NASDAQ:MDWD)July 20, 2025 | marketbeat.comMediWound (NASDAQ:MDWD) Lowered to "Sell" Rating by Wall Street ZenJuly 19, 2025 | marketbeat.comMediWound (NASDAQ:MDWD) Stock Price Passes Above 50 Day Moving Average - Here's WhyJuly 15, 2025 | marketbeat.comMediWound Ltd. (NASDAQ:MDWD) is definitely on the radar of institutional investors who own 42% of the companyJuly 7, 2025 | finance.yahoo.comMediWound Ltd. (MDWD) latest stock news and headlines - Yahoo FinanceJune 26, 2025 | sg.finance.yahoo.comCompanies Like MediWound (NASDAQ:MDWD) Are In A Position To Invest In GrowthJune 2, 2025 | finance.yahoo.comMediWound’s Q1 2025: Strategic Progress Amid Financial ChallengesMay 21, 2025 | tipranks.comMediWound (MDWD) Q1 2025 Earnings Call TranscriptMay 21, 2025 | msn.comMediWound Ltd. (MDWD) Q1 2025 Earnings Call TranscriptMay 21, 2025 | seekingalpha.comMediWound (MDWD) Reports Q1 Loss, Misses Revenue EstimatesMay 21, 2025 | zacks.comMediWound Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 21, 2025 | globenewswire.comMediWound Q1 2025 Earnings PreviewMay 20, 2025 | msn.comMediWound Ltd.: Undervalued High-Growth PotentialMay 16, 2025 | seekingalpha.comMediWound Announces Publication of Phase II EscharEx® Data Demonstrating Superiority Over Collagenase in Venous Leg UlcersMay 13, 2025 | globenewswire.comMediWound to Report First Quarter 2025 Financial ResultsMay 5, 2025 | globenewswire.comMediWound to Present New EscharEx® Data at Leading Wound Care ConferencesApril 28, 2025 | globenewswire.comThose who invested in MediWound (NASDAQ:MDWD) five years ago are up 30%April 17, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeALGS, ELDN, MDWD, and BTMD Company DescriptionsAligos Therapeutics NASDAQ:ALGS$8.00 +0.54 (+7.24%) Closing price 08/4/2025 04:00 PM EasternExtended Trading$7.75 -0.25 (-3.13%) As of 05:45 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.biote NASDAQ:BTMD$4.13 +0.24 (+6.17%) Closing price 08/4/2025 04:00 PM EasternExtended Trading$5.90 +1.77 (+42.86%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female. The company was founded in 2012 and is headquartered in Irving, Texas.Eledon Pharmaceuticals NASDAQ:ELDN$3.25 -0.13 (-3.85%) Closing price 08/4/2025 04:00 PM EasternExtended Trading$3.55 +0.30 (+9.23%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.MediWound NASDAQ:MDWD$18.37 -0.16 (-0.86%) Closing price 08/4/2025 04:00 PM EasternExtended Trading$18.97 +0.60 (+3.26%) As of 08/4/2025 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas How 2 Deals in 48 Hours Changed Everything for Joby Aviation Here's Why Traders Turned Bullish on Boeing Stock Onsemi’s August Pullback Is a Signal to Buy for Tech Investors Strategy Insiders Buy In While Analysts Predict Big Upside Analysts Make a Quantum Bet on D-Wave's Cryogenic Packaging Yes, You Can Get Dividends in Tech: 3 Stocks With Yield + Upside MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
